Taysha Gene Therapies
TSHA
$2.67
Share price
0.75%
Change (1 day)
16.59%
Change (1 year)
Taysha Gene Therapies (TSHA) - Cash on Hand
Cash on Hand as of March 2025 : $0.11 Billion USD
According to Taysha Gene Therapies's latest financial reports the company has $0.11 Billion USD in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Taysha Gene Therapies - Cash on Hand chart (from 2020 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | $0.13 B | -3.41% |
| 2023-12-31 | $0.14 B | 63.79% |
| 2022-12-31 | $87.88 M | -41.06% |
| 2021-12-31 | $0.14 B | -40.66% |
| 2020-12-31 | $0.25 B | |
| 2019-12-31 | N/A |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | $0.20 B | 74.73% | 🇺🇸 USA |